Provides ESMO-PaedCan-EURACAN clinical practice guidelines for the diagnosis, treatment, and follow-up of bone sarcomas.
Answers are grounded in this paper and cite their sources.
Supports referral to expert centers for rare bone sarcomas; extends ESMO guidelines with subtype-specific incidence data for tailored care.
Primary bone tumours are rare, accounting for < 0.2% of malignant neoplasms registered in the EUROCARE (European Cancer Registry based study on survival and care of cancer patients) database [1]. Different bone tumour subtypes have distinct patterns of incidence, and each has no more than 0.3 incident cases per 100 000 per year. Osteosarcoma (OS) and Ewing sarcoma (ES) have a relatively high incidence in the second decade of life, whereas chondrosarcoma (CS) is more common in older age [2–4].
No takes yet. Share an insight, caveat, or question.
Casali et al. (2018) conducted a review in Bone sarcomas. Primary bone tumours are rare malignancies accounting for <0.2% of malignant neoplasms, with distinct incidence patterns across subtypes like osteosarcoma, Ewing sarcoma, and chondrosarcoma.
Synapse has enriched 10 related papers. Consider them for comparative context: